Portal:CPTAC
From WikiPathways
(Adding hallmark display) |
Current revision (09:21, 6 October 2019) (view source) |
||
| (6 intermediate revisions not shown.) | |||
| Line 9: | Line 9: | ||
}} | }} | ||
| - | <div style="float:left; width: | + | <div style="float:left; width:73%"> <!-- This width add to the the margin below to equal 99% --> |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
{{{{FULLPAGENAME}}/box-normal | {{{{FULLPAGENAME}}/box-normal | ||
| Line 34: | Line 23: | ||
</div> | </div> | ||
| - | <div style="float:right; width: | + | <div style="float:right; width:26%"> <!-- This margin should be right of the above --> |
{{{{FULLPAGENAME}}/box-normal | {{{{FULLPAGENAME}}/box-normal | ||
| Line 46: | Line 35: | ||
}} | }} | ||
| + | {{{{FULLPAGENAME}}/box-normal | ||
| + | |<!-- TITLE OF BOX --> | ||
| + | <big>''Assay Portal''</big> | ||
| + | |<!-- EDIT LINK --> | ||
| + | {{FULLPAGENAME}}/AssayPortal | ||
| + | |<!-- CONTENT LINK --> | ||
| + | {{FULLPAGENAME}}/AssayPortal | ||
| + | | | ||
| + | }} | ||
| + | |||
| + | {{{{FULLPAGENAME}}/box-normal | ||
| + | |<!-- TITLE OF BOX --> | ||
| + | <big>''Pathway Curation''</big> | ||
| + | |<!-- EDIT LINK --> | ||
| + | {{FULLPAGENAME}}/Curation | ||
| + | |<!-- CONTENT LINK --> | ||
| + | {{FULLPAGENAME}}/Curation | ||
| + | | | ||
| + | }} | ||
{{{{FULLPAGENAME}}/box-normal | {{{{FULLPAGENAME}}/box-normal | ||
| Line 57: | Line 65: | ||
}} | }} | ||
</div> | </div> | ||
| + | |||
| + | [[Category:Portals]] | ||
Current revision
CPTAC Pathways
Welcome to the CPTAC Pathway PortalThis portal highlights pathway content relevant to the Clinical Proteomic Tumor Analysis Consortium (CPTAC). The National Cancer Institute, part of the National Institutes of Health, announced the launch of a Clinical Proteomic Tumor Analysis Consortium in August 2011. CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. The overarching goal of CPTAC is to improve our ability to diagnose, treat and prevent cancer. To achieve this goal in a scientifically rigorous manner, the NCI launched CPTAC to systematically identify proteins that derive from alterations in cancer genomes and related biological processes, and provide this data with accompanying assays and protocols to the public. The pathways included in this portal have been organized into classic cancer hallmark categories, based on the different biological capabilities acquired during the multistep development of human tumors. To read more, see Hallmarks of cancer: the next generation, Hanahan and Weinberg, Cell 2011. | 
|
Cancer Hallmark Categories
| Sustaining proliferative signaling
Translation inhibitors in chronically activated PDGFRA cells (Homo sapiens) Image does not exist Translation inhibitors in chronically activated PDGFRA cells | Evading growth suppressors
G1 to S cell cycle control (Homo sapiens) Image does not exist G1 to S cell cycle control | Activating invasion and metastasis
H19, Rb-E2F1, and CDK-beta-catenin in colorectal cancer (Homo sapiens) Image does not exist H19, Rb-E2F1, and CDK-beta-catenin in colorectal cancer |
| Enabling replicative immortality
ncRNAs in Wnt signaling in hepatocellular carcinoma (Homo sapiens) Image does not exist ncRNAs in Wnt signaling in hepatocellular carcinoma | Inducing angiogenesis
Model for regulation of MSMP expression in cancer cells and its proangiogenic role in ovarian tumors (Homo sapiens) Image does not exist Model for regulation of MSMP expression in cancer cells and its proangiogenic role in ovarian tumors | Resisting cell death
PI3K-AKT-mTOR signaling and therapeutic opportunities in prostate cancer (Homo sapiens) Image does not exist PI3K-AKT-mTOR signaling and therapeutic opportunities in prostate cancer |
| Deregulating cellular energetics
Glycolysis and gluconeogenesis (Homo sapiens) Image does not exist Glycolysis and gluconeogenesis | Genome instability and mutation
Direct reversal repair (Homo sapiens) Image does not exist Direct reversal repair | Tumor promoting inflammation
Cytokines and inflammatory response (Homo sapiens) Image does not exist Cytokines and inflammatory response |
| Avoiding immune destruction
Altered glycosylation of MUC1 in tumor microenvironment (Homo sapiens) Image does not exist Altered glycosylation of MUC1 in tumor microenvironment | Therapeutics
Imatinib and chronic myeloid leukemia (Homo sapiens) Image does not exist Imatinib and chronic myeloid leukemia |
Featured Pathways
|
Image does not exist PDGFR-beta pathway Zhang, et al. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer |
| View featured pathways |
| List of all pathways for this portal |
Assay Portal
CPTAC also includes an Assay Portal to widely disseminate highly characterized proteomic assays to the global research community, with access to SOPs, reagents, and assay characterization/validation data
Resources
- Over 2400 protein and peptide assays: Browse assays
- Over 750 antibodies and antigen targets: Browse antibodies
- Hundreds of terabytes of data sets: Browse data
Learn how they incorpated WikiPathways images with custom links on their site.
Pathway Curation
On this page you see rotating displays of hallmark and featured pathways. Where did these pathways come from? They came from people like you! The CPTAC set of pathways can be edited, fixed and added to using the pathway drawing and annotation tools here at WikiPathways.
Getting Started
- Introduction to WikiPathways (slides)
- WikiPathways Overview or New Contributor Quickstart
- General help pages
- CPTAC Workshop Exercises
Resources
- Learn more about CPTAC
- Pathway analysis
- Cytoscape and the WikiPathways app
- PathVisio and the WikiPathways plugin
Curation projects
- Curating Hallmark Pathways -- How to
- Example: construction of Pathways in Renal Cancer
- Contact Alex Pico if interested in curating, adding or using CPTAC pathways, [email protected]
